Literature DB >> 26275565

Influence of glycaemic control on the outcomes of patients treated by intravenous thrombolysis for cerebral ischaemia.

Rachel Litke1, Solène Moulin2,3, Charlotte Cordonnier2,3, Pierre Fontaine1, Didier Leys4,5.   

Abstract

Whether the glycaemic control during the first hours of cerebral ischaemia treated by thrombolysis influences outcomes remains unsettled. We aimed at evaluating the quality of the glycaemic control and whether patients with well-controlled glycaemia after thrombolysis for acute cerebral ischaemia have better outcomes. We retrospectively analysed data prospectively collected in consecutive stroke patients who received i.v. thrombolysis at the Lille University Hospital. Patients with glycaemia >1.6 g/l (8.9 mmol/l) at any point during the first 48 h received insulin. We used 2 definitions of well controlled glycaemia: (i) "well controlled 100 %" when 100 % glycaemia were <1.6 g/l (8.9 mmol/l), and (ii) "well controlled 70 %" when at least 70 % glycaemia were <1.6 g/l (8.9 mmol/l). The outcome measures at 3 months were (1) independence [modified Rankin scale (mRS) score 0 or 1], (2) absence of handicap (mRS 0-2), (3) death, and (4) symptomatic intracerebral haemorrhage (sICH). Of 875 consecutive patients, 657 (75.2 %) were considered as well controlled with a threshold at 100 % and 736 (84.2 %) with a threshold at 70 %. The glycaemic control was not independently associated with any of the four outcome measures. In patients treated by insulin, hypoglycaemic events were rare (2.1 % of all patients) and of moderate intensity [>0.5 g/l (2.8 mmol/l)]. The quality of the glycaemic control was not associated with outcomes in patients treated by thrombolysis. A possible explanation is that the glycaemic control after thrombolysis has minor influence compared with glycaemic control before thrombolysis when the artery is not yet re-open and the penumbra area at maximum.

Entities:  

Keywords:  Cerebral haemorrhage; Cerebral ischaemia; Diabetes mellitus; Glycaemic control; Ischaemic stroke; Outcome; Serum glucose level; Symptomatic haemorrhagic transformation; Thrombolysis

Mesh:

Substances:

Year:  2015        PMID: 26275565     DOI: 10.1007/s00415-015-7874-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

Review 2.  Alterations in carbohydrate metabolism during stress: a review of the literature.

Authors:  B A Mizock
Journal:  Am J Med       Date:  1995-01       Impact factor: 4.965

3.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

4.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 6.  Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review.

Authors:  Jean-Philippe Desilles; Elena Meseguer; Julien Labreuche; Bertrand Lapergue; Gaia Sirimarco; Jaime Gonzalez-Valcarcel; Philippa Lavallée; Lucie Cabrejo; Celine Guidoux; Isabelle Klein; Pierre Amarenco; Mikael Mazighi
Journal:  Stroke       Date:  2013-05-23       Impact factor: 7.914

7.  Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.

Authors:  P Lyden; T Brott; B Tilley; K M Welch; E J Mascha; S Levine; E C Haley; J Grotta; J Marler
Journal:  Stroke       Date:  1994-11       Impact factor: 7.914

8.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis.

Authors:  Mayi Gnofam; Didier Leys; Nelly Ponchelle-Dequatre; Marie Bodenant; Hilde Hénon; Régis Bordet; Charlotte Cordonnier
Journal:  J Neurol       Date:  2013-08-14       Impact factor: 4.849

View more
  1 in total

1.  Association of Stress Hyperglycemia Ratio With Acute Ischemic Stroke Outcomes Post-thrombolysis.

Authors:  Chuan-Li Shen; Nian-Ge Xia; Hong Wang; Wan-Li Zhang
Journal:  Front Neurol       Date:  2022-01-13       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.